CN100467469C - A2b腺苷受体拮抗剂 - Google Patents

A2b腺苷受体拮抗剂 Download PDF

Info

Publication number
CN100467469C
CN100467469C CNB02822258XA CN02822258A CN100467469C CN 100467469 C CN100467469 C CN 100467469C CN B02822258X A CNB02822258X A CN B02822258XA CN 02822258 A CN02822258 A CN 02822258A CN 100467469 C CN100467469 C CN 100467469C
Authority
CN
China
Prior art keywords
dione
formula
trihydropurine
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02822258XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1585769A (zh
Inventor
拉奥·卡拉
陶佩里
埃尔法蒂赫·埃尔扎因
维布哈夫·瓦尔凯赫特卡
李小芬
普拉巴·易卜拉欣
文卡塔·帕勒
肖登明
杰夫·扎布沃茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1585769A publication Critical patent/CN1585769A/zh
Application granted granted Critical
Publication of CN100467469C publication Critical patent/CN100467469C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB02822258XA 2001-11-09 2002-11-08 A2b腺苷受体拮抗剂 Expired - Fee Related CN100467469C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34822201P 2001-11-09 2001-11-09
US60/348,222 2001-11-09
US40140802P 2002-08-05 2002-08-05
US60/401,408 2002-08-05

Publications (2)

Publication Number Publication Date
CN1585769A CN1585769A (zh) 2005-02-23
CN100467469C true CN100467469C (zh) 2009-03-11

Family

ID=26995608

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02822258XA Expired - Fee Related CN100467469C (zh) 2001-11-09 2002-11-08 A2b腺苷受体拮抗剂

Country Status (19)

Country Link
US (2) US6825349B2 (https=)
EP (1) EP1444233B1 (https=)
JP (1) JP4350517B2 (https=)
KR (1) KR100937620B1 (https=)
CN (1) CN100467469C (https=)
AT (1) ATE520694T1 (https=)
AU (1) AU2002359365B2 (https=)
CA (1) CA2466477C (https=)
CY (1) CY1112459T1 (https=)
DK (1) DK1444233T3 (https=)
HU (1) HU229504B1 (https=)
IL (2) IL161867A0 (https=)
MX (1) MXPA04004388A (https=)
NO (1) NO329692B1 (https=)
NZ (1) NZ532816A (https=)
PL (1) PL370207A1 (https=)
PT (1) PT1444233E (https=)
RU (1) RU2318824C2 (https=)
WO (1) WO2003042214A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261200A (zh) * 2010-09-13 2013-08-21 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
CN104744469A (zh) * 2014-10-31 2015-07-01 合肥平光制药有限公司 一种茶碱的制备方法

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
WO2002002560A2 (en) * 2000-07-04 2002-01-10 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) * 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
MXPA03008967A (es) * 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
ES2385378T3 (es) 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
AU2011224104B2 (en) * 2003-05-06 2012-06-28 Gilead Sciences, Inc. A2B adenosine receptor antagonists
DE60322748D1 (de) * 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
ES2557310T3 (es) * 2003-08-25 2016-01-25 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
CA2544193C (en) * 2003-10-31 2012-03-27 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
AU2011202523B2 (en) * 2003-11-21 2013-05-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
MX2007002437A (es) * 2004-09-01 2007-08-14 Cv Therapeutics Inc Metodo para el sanado de heridas utilizando antagonistas del receptor de adenosina a2b.
EP1799221A1 (en) * 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
CN101076343A (zh) 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
EP1891070A1 (en) * 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
AU2007227021B2 (en) 2006-03-17 2012-12-20 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
WO2008028140A1 (en) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
US7470697B2 (en) * 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
WO2008086096A2 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
EP2227471A1 (en) * 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
JP2011528364A (ja) * 2008-07-16 2011-11-17 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アテローム性動脈硬化症の治療
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
BR112012032766A2 (pt) * 2010-06-30 2019-09-24 Gilead Sciences Inc uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012055015A1 (en) * 2010-10-26 2012-05-03 Alberta Health Services Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
EP2465859A1 (en) * 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
CA2853633A1 (en) * 2011-10-27 2013-05-02 Proteotech Inc Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies
CN102532137B (zh) * 2011-12-05 2014-12-10 辽宁医学院 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用
US9035071B2 (en) * 2011-12-27 2015-05-19 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2899646C (en) 2013-03-15 2021-08-31 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
WO2017060488A1 (en) * 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017139455A1 (en) 2016-02-10 2017-08-17 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
ES2975753T3 (es) 2018-03-05 2024-07-12 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
KR20210061202A (ko) 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
KR20210076693A (ko) 2019-12-16 2021-06-24 일동제약(주) 질소를 포함하는 헤테로고리로 치환된 축합 피리미딘 유도체 및 그의 의약 용도
EP4554943A1 (en) * 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879296A (en) * 1985-04-27 1989-11-07 Burroughs Wellcome Co. Xanthine derivatives
US5532368A (en) * 1988-12-22 1996-07-02 Boehringer Ingelheim Gmbh Xanthine derivatives with adenosine-antagonistic activity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4452788A (en) 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1999042092A2 (en) 1998-02-20 1999-08-26 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
ES2189079T3 (es) 1998-04-24 2003-07-01 Leuven K U Res & Dev Efectos inmunosupresores de derivados de xantina 8-sustituidos.
DE29902571U1 (de) 1998-05-19 2000-03-23 Papst-Motoren GmbH & Co. KG, 78112 St Georgen Elektronisch kommutierter Motor
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
CA2333947C (en) * 1998-06-01 2010-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6437154B1 (en) 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879296A (en) * 1985-04-27 1989-11-07 Burroughs Wellcome Co. Xanthine derivatives
US5532368A (en) * 1988-12-22 1996-07-02 Boehringer Ingelheim Gmbh Xanthine derivatives with adenosine-antagonistic activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
1,3-dialkylxanthine deverivatives having hingh potency. Jaconbson K et al.Drug development research,Vol.47 No.1. 1999 *
reactions of theophyllines. KUZ MENKO I I et al.chemistry of heterocyclic compounds,Vol.36 No.8. 2000 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261200A (zh) * 2010-09-13 2013-08-21 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
CN104744469A (zh) * 2014-10-31 2015-07-01 合肥平光制药有限公司 一种茶碱的制备方法

Also Published As

Publication number Publication date
JP2005509036A (ja) 2005-04-07
NZ532816A (en) 2005-11-25
HK1071127A1 (en) 2005-07-08
NO20042378L (no) 2004-07-20
RU2004114210A (ru) 2005-09-10
WO2003042214A3 (en) 2004-03-04
KR20050044361A (ko) 2005-05-12
MXPA04004388A (es) 2005-05-16
HU229504B1 (hu) 2014-01-28
IL161867A0 (en) 2005-11-20
IL161867A (en) 2015-01-29
ATE520694T1 (de) 2011-09-15
PT1444233E (pt) 2011-09-29
AU2002359365A2 (en) 2003-05-26
NO329692B1 (no) 2010-12-06
WO2003042214A2 (en) 2003-05-22
HUP0401925A2 (hu) 2005-01-28
AU2002359365B2 (en) 2008-07-10
CA2466477C (en) 2012-10-02
EP1444233B1 (en) 2011-08-17
RU2318824C2 (ru) 2008-03-10
CY1112459T1 (el) 2015-12-09
DK1444233T3 (da) 2011-10-17
PL370207A1 (en) 2005-05-16
US20030139428A1 (en) 2003-07-24
US7105665B2 (en) 2006-09-12
JP4350517B2 (ja) 2009-10-21
US6825349B2 (en) 2004-11-30
US20050038045A1 (en) 2005-02-17
CA2466477A1 (en) 2003-05-22
KR100937620B1 (ko) 2010-01-20
CN1585769A (zh) 2005-02-23
HUP0401925A3 (en) 2007-05-29
EP1444233A2 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
CN100467469C (zh) A2b腺苷受体拮抗剂
US8324224B2 (en) A2B adenosine receptor antagonists
US6977300B2 (en) A2B adenosine receptor antagonists
CN100415748C (zh) A2b腺苷受体拮抗剂
US7449473B2 (en) Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
AU2002359365A1 (en) A2B adenosine receptor antagonists
US7304070B2 (en) A2B adenosine receptor antagonists
CA2524778C (en) Xanthine derivatives as a2b adenosine receptor antagonists
RU2318825C2 (ru) Производные ксантина в качестве антагонистов a2b аденозинового рецептора
HK1071127B (en) A2b adenosine receptor antagonists
KR20060055453A (ko) Ａ2ｂ 아데노신 수용체 길항제로서의 크산틴 유도체
HK1092137B (en) Xanthine derivatives as a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD.

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100519

Address after: American California

Patentee after: Cv Therapeutics Inc.

Address before: American California

Patentee before: CV Therapeutics Inc.

ASS Succession or assignment of patent right

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER: GILEAD PALO ALTO, INC.

Effective date: 20140528

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140528

Address after: American California

Patentee after: Gilead Sciences Corporation

Address before: American California

Patentee before: Cv Therapeutics Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090311

Termination date: 20191108

CF01 Termination of patent right due to non-payment of annual fee